BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $442,500 | -44.9% | 62,500 | -35.1% | 0.01% | -53.3% |
Q1 2023 | $803,142 | -76.0% | 96,300 | -67.0% | 0.02% | -71.2% |
Q4 2022 | $3,347,568 | -8.8% | 291,600 | 0.0% | 0.05% | +4.0% |
Q3 2022 | $3,672,000 | -56.4% | 291,600 | -63.4% | 0.05% | -56.9% |
Q2 2022 | $8,419,000 | -36.5% | 795,700 | -2.4% | 0.12% | -27.0% |
Q1 2022 | $13,251,000 | +110.4% | 815,000 | +79.3% | 0.16% | +123.9% |
Q4 2021 | $6,298,000 | -50.7% | 454,500 | -48.9% | 0.07% | -51.4% |
Q3 2021 | $12,769,000 | -55.4% | 888,600 | -50.9% | 0.15% | -61.0% |
Q2 2021 | $28,634,000 | +716.2% | 1,810,800 | +424.9% | 0.37% | +392.1% |
Q1 2021 | $3,508,000 | +175.6% | 345,000 | -6.4% | 0.08% | +76.7% |
Q4 2019 | $1,273,000 | +1283.7% | 368,700 | +1411.1% | 0.04% | +760.0% |
Q2 2019 | $92,000 | -54.7% | 24,400 | -2.4% | 0.01% | -54.5% |
Q1 2019 | $203,000 | – | 25,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |